PRO-LAD

N,N-diethyl-6-propyl-9,10-didehydroergoline-8β-carboxamide

6Node page

what any key link opens

psx:substance/pro-lad/search/e5d53393-3d0c-4976-b190-90a7c791ea14

search2026-04-27recorddocument_retrieval

derived from · upstream

none recorded

feeds · downstream

usedGeneration — pipeline-v5psx:substance/pro-lad/gen/9fad63cc-ba94-4736-9256-9bbe4117c35f

psx:substance/pro-lad/search/e5d53393-3d0c-4976-b190-90a7c791ea14
  ├─ used  search/14f8b142-a94e-44d0-abc0-0bcb6fb51a72  Searched PubChem for "PRO-LAD"
  ├─ used  search/5af9fa60-ec4a-4bbf-a559-b03877c89553  Searched PubMed for "PRO-LAD lysergamide psychedelic pharmacology"
  ├─ used  search/5c6d0e37-cdc7-4e26-b30e-b00a8729ec4a  Searched PubMed for "N-propyl lysergamide serotonin receptor binding"
  ├─ used  search/8015600b-0c99-43a8-8c17-9122852196c4  Searched ClinicalTrials.gov for "PRO-LAD lysergamide"
  ├─ used  search/119de8c5-9284-4946-911d-93126e7f79b8  Searched PubMed for "PMID 4032428"
  ├─ used  search/d731e18c-b35b-43b1-b7e9-d87161518842  Searched WebSearch for "PRO-LAD N-propyl-nor-lysergic acid diethylamide pharmacology synthesis Nichols"
  ├─ used  search/3af51be2-f3f4-4ea5-bc45-0cc918501943  Searched WebSearch for "PRO-LAD lysergamide legal status scheduling UK US Australia"
  ├─ used  search/413a54b2-241e-4a5b-b599-b9f09134b80e  Searched WebFetch
  ├─ used  search/a0f4a4ce-9dc8-42f8-90f7-5f421b21f2ab  Searched PubMed for "Hoffman Nichols 1985 lysergamide diethylamide psychedelic analog SAR"
  ├─ used  search/d6d547be-631d-4a19-a074-ae0bc0527e6c  Searched WebSearch for "PRO-LAD TiHKAL Shulgin Nichols 1986 human effects receptor binding Ki"
  ├─ used  search/df132575-7d6c-4792-87f2-4e122f7e6e4f  Searched PubMed for "PMID 19040555"
  ├─ used  search/63f9b394-fabf-4287-a371-80d0b45e6e70  Searched PubMed for "PMID 28197931"
  ├─ used  search/a23cda69-5657-4d2f-a4da-39ddac68a299  Searched Erowid/TiHKAL
  ├─ used  search/e04f5f41-3d2a-4ffe-bffb-c16aaab5f811  Searched UK Home Office
  ├─ used  search/4f61705c-2508-45a4-94c0-991ba9726a8d  Searched WebSearch for "PRO-LAD legal status Sweden Switzerland Latvia Australia Canada scheduling"
  ├─ used  search/1b734c93-948e-4384-9f05-21f61937537c  Searched WebFetch
  ├─ used  search/740a9bc1-1115-4610-9e69-806522463e7d  Searched WebSearch for "Return of the lysergamides PRO-LAD part IV Brandt Halberstadt"
  ├─ used  search/ced56ef3-4657-4486-82ce-f1d677d75b33  Searched PubChem REST API
  ├─ used  search/b3ae05d2-415a-445a-b304-ba254c88f4b8  Searched PubMed for "PMID 26108222"
  ├─ used  search/4ceca026-269a-4885-b5a2-651b8bfc6422  Searched Crossref/DOI verification for "10.1021/jm00147a022"
  ├─ used  search/c6da1f4d-5061-4891-83af-2dbebeb486f5  Searched PubMed for "Rickli Moning Hoener Liechti receptor profiling 2016"
  ├─ used  search/4ce95b98-2be4-4f41-b823-822cd2cb4b6f  Searched WebSearch for "LSD pharmacokinetics Dolder 2017 half-life Tmax Cmax"
  ├─ used  search/a518146c-1423-457a-9d54-4cc200d412d3  Searched WebFetch
  ├─ used  search/41c3a635-ed96-4866-9267-8854c6e9ddbf  Searched ClinicalTrials.gov for "PRO-LAD lysergamide"
    ├─ used  src/pmid:4032428  Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives
    ├─ used  src/url:06602f5bdaee7d4c  TiHKAL: Tryptamines I Have Known and Loved — Entry #51 PRO-LAD
    ├─ used  src/url:41bdc545a368054f  Home Office Circular 001/2015: Control of AH-7921, LSD-related compounds, tryptamines, and rescheduling of GHB
    ├─ used  src/doi:10.1111/j.1755-5949.2008.00059.x  The pharmacology of lysergic acid diethylamide: a review
    ├─ used  src/url:0a4bf986a2dbcb24  PRO-LAD: The Forgotten LSD-Alternative - Tripsitter
    ├─ used  src/url:2938641e7ac0608d  PRO-LAD - Wikipedia
    ├─ used  src/doi:10.1002/dta.1985  Return of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)
    ├─ used  src/doi:10.1002/dta.2196  Return of the lysergamides. Part III: Analytical characterization of ETH-LAD and 1P-ETH-LAD
    ├─ used  src/doi:10.1016/j.neuron.2025.06.012  The polypharmacology of psychedelics reveals multiple targets for potential therapeutics
    ├─ used  src/doi:10.1016/j.cell.2016.12.033  Crystal Structure of an LSD-Bound Human Serotonin Receptor
    ├─ used  src/doi:10.1016/j.euroneuro.2016.05.001  Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
    ├─ used  src/doi:10.1093/ijnp/pyv072  Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans
    ├─ used  src/doi:10.1007/s40262-017-0513-9  Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
    ├─ used  src/doi:10.1007/s00213-022-06142-4  The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides
    ├─ used  src/doi:10.1002/hup.2599  Genie in a blotter: A comparative study of LSD and LSD analogues' effects and user profile
    ├─ used  src/doi:10.3389/fpsyt.2019.00896  Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics
    ├─ used  src/doi:10.1007/s40265-021-01515-z  Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles
    └─ generated_by  pub/f1c0e53d-38cb-4bd6-82fc-11f5588a4e05  Publication — backfill
├─ used  gen/9fad63cc-ba94-4736-9256-9bbe4117c35f  Generation — pipeline-v5
  ├─ derived_from  version/1  Revision 1
    ├─ derived_from  issue/notice@64878b43a1d2  Issued notice
    ├─ derived_from  issue/info_card@9ba6b221d406  Issued info_card
    ├─ derived_from  issue/emergency@3f0909c25c71  Issued emergency
    ├─ derived_from  issue/notice@f069a9dea47b  Issued notice
    ├─ derived_from  issue/info_card@dda4886118b4  Issued info_card
    ├─ derived_from  issue/emergency@c15c760aabf6  Issued emergency
      ├─ used  claim/26fb33db-c05b-449f-ad6b-0be8508121af  Claim in receptor-pharmacology — supported
      ├─ used  claim/f3166a55-3e6e-4648-9e7d-636ef18862d3  Claim in summary — inconclusive  working
      ├─ used  claim/2c5ae8c2-91f6-4b0a-8fa4-33d7c648a0eb  Claim in summary — supported
      ├─ used  claim/62548f01-b625-4241-993b-5582520a2330  Claim in pharmacology — supported
      ├─ used  claim/aa76f6d3-bd3e-4afc-bfc5-9c4a0af212fa  Claim in history — supported
      ├─ used  claim/7af9e2a1-7890-4daa-9673-55472f07d68b  Claim in history — supported
      ├─ used  claim/86c6a1d0-f772-4014-983e-29eb3c6bf69c  Claim in chemistry — supported
      ├─ used  claim/9e458173-54b3-418e-98c7-6f79e87083e5  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/758cba4a-a019-47df-82a7-3d590176324d  Claim in comparative-pharmacology — supported
      ├─ used  claim/01305750-92c1-4093-9913-2b4085b0d2fe  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/2757cdfa-dfad-4a7a-a734-54b78c203c27  Claim in safety — inconclusive  working
      ├─ used  claim/21758e3b-fd24-48da-ac9c-a84c7d28c664  Claim in safety — inconclusive  working
      ├─ used  claim/d6ec1ada-34ac-471d-9f0d-e31373692618  Claim in summary — supported
      ├─ used  claim/d37e3f43-4c18-4e10-8b69-47d3608354cb  Claim in summary — supported
      ├─ used  claim/ed832f79-f610-4040-86fa-80120b23767a  Claim in summary — inconclusive  working
      ├─ used  claim/4506f2b4-f442-4058-b612-09f07bc487ed  Claim in pharmacology — supported
      ├─ used  claim/f3751a33-cc0f-419e-a39f-8cfc955df4b7  Claim in safety — inconclusive  working
      ├─ used  claim/eb4ed634-33e2-41c4-a522-2138c76e015c  Claim in pharmacology — inconclusive  working
      ├─ used  claim/e4fd1a59-17fb-4f53-8c9e-75cacbf58dc6  Claim in safety — supported
      ├─ used  claim/95622543-06a5-4211-af81-51c0a9a56c0b  Claim in safety — inconclusive  working
      ├─ used  claim/af246ac7-1eff-4467-bc03-e9c18690b1ce  Claim in safety — inconclusive  working
      ├─ used  claim/cebd7ef3-5c2e-49a4-8103-76646d78fad9  Claim in safety — inconclusive  working
      ├─ used  claim/d6da2e95-e08d-41e5-9b3f-428fffb74593  Claim in chemistry — inconclusive  working
      ├─ used  claim/935788b0-bfd6-45ff-8efb-6507cdb02ffd  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/1450efb7-591a-4578-b6eb-3b732acd6915  Claim in neuroscience — inconclusive  working
      ├─ used  claim/0a603caa-bc92-4844-9c7c-4b2eff8e64af  Claim in history — supported
      ├─ used  claim/531ccf3c-18cf-4ff6-91f8-2676a83e15ad  Claim in history — supported
      ├─ used  claim/795fd8a3-1b10-4983-9be6-2a6270f2e000  Claim in pharmacology — supported
      ├─ used  claim/f9c682c7-1139-4c26-ba96-0fb3e5251ba4  Claim in chemistry — inconclusive  working
      ├─ used  claim/aeaeb9d1-5c95-422a-be88-31739a38ef99  Claim in pharmacology — supported
      ├─ used  claim/16992791-6121-4298-909d-b7e2f9c49d7f  Claim in pharmacology — supported
      ├─ used  claim/b6032908-94f1-4d10-b637-bc8329f4c9c9  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/96c844de-140e-4c04-97fc-99c61899d55e  Claim in neuroscience — supported
      ├─ used  claim/22b30a0c-cfaf-4dfe-bf9f-aec990f313ff  Claim in pharmacology — supported
      ├─ used  claim/26f2477d-f5ab-4447-b5b1-4b1ea6557c06  Claim in receptor-pharmacology — supported
      ├─ used  claim/cdd250bb-af92-4927-b43e-329b84908723  Claim in neuroscience — supported
      ├─ used  claim/1dc38b0d-4a9b-4190-98a7-2c3027496fd5  Claim in pharmacology — supported
      ├─ used  claim/da7f8ebf-20d2-44eb-8bb4-39c8dbe60bf0  Claim in pharmacology — supported
      ├─ used  claim/95d0cef7-9327-437d-9182-a0dc90cebdb7  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/799b4153-dd5d-4cab-9bff-5c90e6eefe71  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/1ea37851-d13e-409b-8f78-72cfdd1b2f2c  Claim in clinical-evidence — supported
      ├─ used  claim/f98b4a3f-bb93-4a24-853b-b661adb07cd5  Claim in clinical-evidence — supported
      ├─ used  claim/94fc1996-b6ae-4a0d-acf6-ddfb71c6040a  Claim in clinical-evidence — supported
      ├─ used  claim/6b39dc7c-28b1-4f65-b344-b721cee9c662  Claim in safety — supported
      └─ used  claim/af7230d8-fb6e-49eb-804a-bbad5af93cf3  Claim in safety — inconclusive  working
… closure truncated at 200 nodes

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

1712 with DOI

4 strong · 9 moderate · 4 weak

Compilations

22026-04-27T07:21:33.829Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

31last ruled 2026-06-04

0 awaiting a ruling

Issued documents

62026-10-19T20:33:45.928Z

notice · info card · emergency

Searches

253 with no results

queries and counts on the build

Claims checked

4529 supported

29 supported · 16 not

Correspondence

0received

consent field ships in Phase 4

Edges

180

derivations recorded for this entity

Complete over 17 sources, 2 compilations, and 31 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/pro-lad/archive

2Build

one panel per compilation run

generation run 2026-04-26

11 min failedmodel not recordedplan not recordedrun/c129ada7…

research

no artifact

draft

no artifact

audit

no artifact

verify

no artifact

simplify

no artifact

publish

no artifact

Selection

results seen0

selected by the model0

consumed as sources17

Verification

claims checked0

supported0

partially supported0

not supported0

inconclusive0

record
seen / partial
working

The model's own caveats

none raised on this run

Reproduce

inputs: 17 source keys (listed under Sources)
plan: not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model: not recorded
streams: none — agent transcripts are persisted from 2026-09 onward

generation run 2026-04-27

47 min completedmodel pipeline-v5plan not recordedrun/cc22b5ac…

Selection

results seen90

selected by the model29

consumed as sources17

Verification

claims checked45

supported29

partially supported0

not supported0

inconclusive16

record
seen / partial
working

The model's own caveats

inferred_pharmacology
sparse_human_data

Reproduce

inputs: 17 source keys (listed under Sources)
plan: not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model: pipeline-v5
streams: none — agent transcripts are persisted from 2026-09 onward

25 searches — query, source, results, what was kept and why

25 searches for this run
#	source	query	seen	kept	rationale
1	PubMed	PMID 4032428	1	1	Primary source for PRO-LAD synthesis and first pharmacological characterization
2	PubChem	PRO-LAD	1	1	Primary chemical identity confirmation
3	WebSearch	PRO-LAD lysergamide legal status scheduling UK US Australia	10	1	Legal status verification
4	WebFetch	—	1	1	Community-sourced dosage information for comparison
5	PubMed	PRO-LAD lysergamide psychedelic pharmacology	15	3	Relevant to pharmacological class; AL-LAD closely related to PRO-LAD
6	PubMed	N-propyl lysergamide serotonin receptor binding	1	1	SAR data for N-alkyl lysergamides
7	ClinicalTrials.gov · absence	PRO-LAD lysergamide	0	—	No results to select
8	PubMed · absence	Hoffman Nichols 1985 lysergamide diethylamide psychedelic analog SAR	0	—	Already found via direct PMID
9	WebSearch	PRO-LAD TiHKAL Shulgin Nichols 1986 human effects receptor binding Ki	10	1	Primary source for human effects data
10	WebSearch	PRO-LAD N-propyl-nor-lysergic acid diethylamide pharmacology synthesis Nichols	10	2	Background context for history and effects
11	WebFetch	—	1	1	Multi-jurisdiction legal status summary
12	WebSearch	PRO-LAD legal status Sweden Switzerland Latvia Australia Canada scheduling	10	1	Legal status data for multiple jurisdictions
13	PubMed	PMID 28197931	1	1	Only human PK study for lysergamide class; used as structural analog reference
14	WebSearch	Return of the lysergamides PRO-LAD part IV Brandt Halberstadt	10	0	No PRO-LAD-specific paper found in Return of the Lysergamides series
15	Erowid/TiHKAL	—	1	1	Primary source for PRO-LAD human effects and physical properties
16	PubChem REST API	—	1	3	Chemical identity verification
17	PubMed	PMID 19040555	1	1	Primary pharmacology review for LSD class; directly applicable to PRO-LAD
18	UK Home Office	—	1	1	Primary government source for UK legal status
19	ClinicalTrials.gov · absence	PRO-LAD lysergamide	0	—	Confirmed absence of clinical trial data
20	WebSearch	LSD pharmacokinetics Dolder 2017 half-life Tmax Cmax	10	2	LSD PK data for class reference
21	Crossref/DOI verification	10.1021/jm00147a022	1	1	Verification of primary PRO-LAD synthesis paper DOI
22	WebFetch	—	1	3	Comprehensive multi-jurisdiction legal status and harm reduction data
23	PubMed	PMID 26108222	1	1	LSD PK reference for class analog inference
24	PubMed	Rickli Moning Hoener Liechti receptor profiling 2016	1	1	LSD receptor profile context applicable to PRO-LAD
25	PubMed	PMID 28129538	1	1	Structural basis for LSD/lysergamide binding kinetics; applies to PRO-LAD by analogy

45 claims by section — every cited sentence, checked against its source

pharmacology9 · 8 ok

PRO-LAD's psychedelic activity is presumed to arise from partial agonism at the serotonin 5-HT₂A receptor (HTR2A), the principal molecular target mediating classical psychedelic effectssupported
Comprehensive review of LSD pharmacology covering synthesis, mechanisms, receptor pharmacology, tolerance, safety. j.1755-5949.2008.00059.x
PRO-LAD's psychedelic activity is presumed to arise from partial agonism at the serotonin 5-HT₂A receptor (HTR2A), the principal molecular target mediating classical psychedelic effectssupported
Provides structural basis for LSD binding at serotonin receptors including 5-HT2A. j.cell.2016.12.033
This mechanistic assignment rests on three lines of evidence: (1) structural identity with lsd at the pharmacophore — the ergoline scaffold and C-8β diethylamide moiety are preserved; (2) complete generalization to the LSD discriminative stimulus in rats, demonstrating equivalent receptor engagement in vivo; and (3) the shared pharmacological profile of all psychoactively potent members of the N⁶-alkyl norlysergamide series.supported
The N(6)-propyl was equipotent to LSD, while the isopropyl derivative was half as active. The N(6)-ethyl and -allyl were approximately 2-3 times more potent than LSD. pmid:4032428
Claim in pharmacology — inconclusiveinconclusiveworking →
LSD acts as a partial agonist at 5-HT₁A (contributing anxiolytic components) and 5-HT₂C receptors, interacts agonistically and antagonistically with dopamine D₁ and D₂ receptors (which may mediate later-phase effects), and engages α₁ and α₂ adrenergic receptors — a profile that distinguishes lysergamides from tryptamine psychedelicssupported
LSD interacted with adrenergic and dopaminergic receptors in contrast to tryptamines. All compounds acted at 5-HT2A. j.euroneuro.2016.05.001
A 2025 comprehensive profiling study of 41 psychedelics against 318 human GPCRs confirmed that lysergamides possess potent activity at nearly every serotonin, dopamine, and adrenergic receptor subtypesupported
41 classical psychedelics profiled against 318 human GPCRs. Psychedelics have potent actions at nearly every serotonin, dopamine, and adrenergic receptor. j.neuron.2025.06.012
The crystal structure of LSD bound to the human 5-HT₂B receptor revealed that an extracellular loop 2 (EL2) "lid" clamps over the ligand within the binding pocket, explaining LSD's prolonged receptor residence time relative to its plasma half-lifesupported
Crystal structure of LSD in complex with human 5-HT2B. Reveals EL2 lid mechanism explaining LSD's exceptionally slow dissociation kinetics. j.cell.2016.12.033
All pharmacokinetic inferences derive from LSD class data.supported
First modern pharmacokinetic characterization of oral LSD in humans. pyv072
Plasma elimination follows a biexponential model with an initial half-life of ~3.6 hours and a terminal half-life of ~8.9 hourssupported
Tmax ~1.5h, half-life 3.6h (initial)/8.9h (terminal). pyv072

safety9 · 2 ok

Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
By structural analogy, PRO-LAD's toxicity profile is expected to resemble that of LSD, which is physiologically well tolerated at typical psychoactive doses with no established lethal dose in humanssupported
LSD physiologically well tolerated; psychological reactions controllable in supervised settings. j.1755-5949.2008.00059.x
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Tramadol's active metabolite O-desmethyltramadol is a potent serotonin reuptake inhibitor, and the combination with a direct 5-HT₂A agonist creates serotonin syndrome risksupported
Tramadol has mixed mechanism: mu-opioid agonism and serotonin/norepinephrine reuptake inhibition. Serotonergic adverse effects documented. s40265-021-01515-z
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →

summary5 · 3 ok

Claim in summary — inconclusiveinconclusiveworking →
First synthesized as part of a systematic N⁶-alkyl norlysergamide series, PRO-LAD was pharmacologically characterized by Hoffman and Nichols in 1985 and documented with first-person human accounts by Shulgin in TiHKAL (1997)supported
A convenient method for the synthesis of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives was developed. A series of these compounds was synthesized and tested for substitution in the two-lever drug discrimination assay pmid:4032428
As a lysergamide sharing LSD's ergoline scaffold and diethylamide moiety, PRO-LAD is presumed to act primarily through partial agonism at the 5-HT₂A receptor, with secondary engagement of 5-HT₁A, dopaminergic, and adrenergic targetssupported
Comprehensive review of LSD pharmacology covering synthesis, mechanisms, receptor pharmacology, tolerance, safety. j.1755-5949.2008.00059.x
By structural analogy with LSD — which is physiologically well tolerated at typical doses with no established human lethal dose — acute physiological toxicity is expected to be lowsupported
LSD physiologically well tolerated; psychological reactions controllable in supervised settings. j.1755-5949.2008.00059.x
Claim in summary — inconclusiveinconclusiveworking →

history4 · 4 ok

Nichols at Purdue University published the synthesis and pharmacological evaluation of a series of N⁶-alkyl norlysergic acid N,N-diethylamide derivativessupported
A convenient method for the synthesis of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives was developed. A series of these compounds was synthesized and tested for substitution in the two-lever drug discrimination assay pmid:4032428
Hoffman and Nichols established that PRO-LAD was equipotent to LSD in a rat two-lever drug discrimination assay, placing it at the boundary between optimal and suboptimal N⁶ substituent size.supported
The N(6)-propyl was equipotent to LSD, while the isopropyl derivative was half as active. The N(6)-ethyl and -allyl were approximately 2-3 times more potent than LSD. pmid:4032428
No dedicated analytical characterization paper for PRO-LAD exists within the "Return of the Lysergamides" series, which has covered the related compounds 1P-LSD, AL-LAD, LSZ, ETH-LAD, and 1P-ETH-LADsupported
Characterization of AL-LAD and LSZ. dta.1985
No dedicated analytical characterization paper for PRO-LAD exists within the "Return of the Lysergamides" series, which has covered the related compounds 1P-LSD, AL-LAD, LSZ, ETH-LAD, and 1P-ETH-LADsupported
Characterization of ETH-LAD (N6-ethyl analog) and its prodrug. dta.2196

receptor-pharmacology4 · 2 ok

Receptor pharmacology is entirely inferred from LSD class data and from the in vivo finding that PRO-LAD is equipotent to LSD in rat drug discrimination.supported
The N(6)-propyl was equipotent to LSD pmid:4032428
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
LSD Ki ranges compiled from multiple published receptor profiling studiessupported
Receptor binding affinities at human monoamine receptors for novel tryptamines vs. classic hallucinogens. j.euroneuro.2016.05.001
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

chemistry3 · 1 ok

The systematic modification of N⁶ substituents — from nor (unsubstituted) through methyl (LSD), ethyl (eth-lad), allyl (al-lad), propyl (PRO-LAD), and larger alkyl groups — constitutes a well-defined structure-activity relationship series first characterized by Hoffman and Nichols.supported
A convenient method for the synthesis of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives was developed. A series of these compounds was synthesized and tested pmid:4032428
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →

clinical-evidence3 · 3 ok

Population survey data on novel lysergamide use patterns have been published, but these studies aggregate data across multiple lysergamide analogs and do not provide PRO-LAD-specific clinical outcomes.supported
Survey study of novel psychedelic use patterns. Little known about use profiles or subjective effects across NP classes. s00213-022-06142-4
Population survey data on novel lysergamide use patterns have been published, but these studies aggregate data across multiple lysergamide analogs and do not provide PRO-LAD-specific clinical outcomes.supported
Survey study comparing self-reported effects of LSD analogues (AL-LAD, 1P-LSD, ETH-LAD) vs LSD. hup.2599
Population survey data on novel lysergamide use patterns have been published, but these studies aggregate data across multiple lysergamide analogs and do not provide PRO-LAD-specific clinical outcomes.supported
Large nationally representative population survey evaluating therapeutic potential of classic and novel psychedelics including lysergamides. fpsyt.2019.00896

neuroscience3 · 2 ok

Claim in neuroscience — inconclusiveinconclusiveworking →
LSD also engages dopaminergic and adrenergic signaling, which contributes to mesolimbic reward modulation and sympathetic arousal, respectivelysupported
LSD interacted with adrenergic and dopaminergic receptors in contrast to tryptamines. j.euroneuro.2016.05.001
The compound's prolonged receptor residence time at 5-HT₂A/₂B — maintained by the EL2 lid mechanism — produces a sustained pharmacological perturbation that outlasts plasma drug levels, a feature likely shared to a lesser degree by PRO-LAD given its shorter duration.supported
Reveals EL2 lid mechanism explaining LSD's exceptionally slow dissociation kinetics. Provides structural basis for LSD binding at serotonin receptors including 5-HT2A. j.cell.2016.12.033

pharmacokinetic-detail3 · 3 ok

The following LSD pharmacokinetic data serve as the best available reference for this lysergamide.supported
First modern pharmacokinetic characterization of oral LSD in humans. pyv072
The following LSD pharmacokinetic data serve as the best available reference for this lysergamide.supported
LSD pharmacokinetics and exposure-response relationship in healthy subjects following oral administration. s40262-017-0513-9
Altered receptor residence time: The n-propyl group may interfere with the EL2 lid-trapping mechanism identified at the 5-HT₂A/₂B binding pocket, leading to faster dissociation.supported
Reveals EL2 lid mechanism explaining LSD's exceptionally slow dissociation kinetics. j.cell.2016.12.033

comparative-pharmacology2 · 1 ok

PRO-LAD's pharmacological position is best understood within the N⁶-alkyl norlysergamide series systematically characterized by Hoffman and Nicholssupported
A convenient method for the synthesis of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives was developed. A series of these compounds was synthesized and tested pmid:4032428
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

3Sources

17 consumed · sorted by year · feeds = sections resting on it

Sources
year	source	tier	status	feeds
2025	The polypharmacology of psychedelics reveals multiple targets for potential therapeuticsJain MK, Gumpper RH, Slocum ST, Schmitz GP, Madsen JS, Tummino TA, Suomivuori CM, Huang XP, Shub L, DiBerto JF, Kim K, DeLeon C, Krumm BE, Fay JF, Keiser M, Hauser AS, Dror RO, Shoichet B, Gloriam DE, Nichols DE, Roth BL · Neurondoi:10.1016/j.neuron.2025.06.012	strong	consumed	2 sections
2024	PRO-LAD - Wikipediaurl:2938641e7ac0608d	weak	consumed	cited only
2024	PRO-LAD: The Forgotten LSD-Alternative - Tripsitterurl:0a4bf986a2dbcb24	weak	consumed	cited only
2022	The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamidesMallaroni P, Mason NL, Vinckenbosch FRJ, Ramaekers JG · Psychopharmacologydoi:10.1007/s00213-022-06142-4	moderate	consumed	1 section
2021	Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety ProfilesRoulet L, Rollason V, Desmeules J, Piguet V · Drugsdoi:10.1007/s40265-021-01515-z	moderate	consumed	1 section
2019	Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide PsychedelicsSexton JD, Nichols CD, Hendricks PS · Frontiers in Psychiatrydoi:10.3389/fpsyt.2019.00896	moderate	consumed	1 section
2017	Crystal Structure of an LSD-Bound Human Serotonin ReceptorWacker D, Wang S, McCorvy JD, Betz RM, Venkatakrishnan AJ, Levit A, Lansu K, Schools ZL, Che T, Nichols DE, Shoichet BK, Dror RO, Roth BL · Celldoi:10.1016/j.cell.2016.12.033	moderate	consumed	3 sections
2017	Genie in a blotter: A comparative study of LSD and LSD analogues' effects and user profileConey LD, Maier LJ, Ferris JA, Winstock AR, Barratt MJ · Human Psychopharmacologydoi:10.1002/hup.2599	moderate	consumed	1 section
2017	Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy SubjectsDolder PC, Schmid Y, Steuer AE, Kraemer T, Rentsch KM, Hammann F, Liechti ME · Clinical Pharmacokineticsdoi:10.1007/s40262-017-0513-9	strong	consumed	1 section
2017	Return of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Colestock T, Burrow TE, Chapman SJ, Stratford A, Nichols DE, Halberstadt AL · Drug Testing and Analysisdoi:10.1002/dta.1985	moderate	consumed	1 section
2017	Return of the lysergamides. Part III: Analytical characterization of ETH-LAD and 1P-ETH-LADBrandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Stratford A, Nichols DE, Halberstadt AL · Drug Testing and Analysisdoi:10.1002/dta.2196	moderate	consumed	1 section
2016	Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogensRickli A, Moning OD, Hoener MC, Liechti ME · European Neuropsychopharmacologydoi:10.1016/j.euroneuro.2016.05.001	strong	consumed	3 sections
2015	Home Office Circular 001/2015: Control of AH-7921, LSD-related compounds, tryptamines, and rescheduling of GHBUK Home Officeurl:41bdc545a368054f	weak	consumed	cited only
2015	Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in HumansDolder PC, Schmid Y, Haschke M, Rentsch KM, Liechti ME · International Journal of Neuropsychopharmacologydoi:10.1093/ijnp/pyv072	strong	consumed	2 sections
2008	The pharmacology of lysergic acid diethylamide: a reviewPassie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A · CNS Neuroscience and Therapeuticsdoi:10.1111/j.1755-5949.2008.00059.x	moderate	consumed	6 sections
1997	TiHKAL: Tryptamines I Have Known and Loved — Entry #51 PRO-LADShulgin A, Shulgin Aurl:06602f5bdaee7d4c	insufficient	consumed	cited only
1985	Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivativesHoffman AJ, Nichols DE · Journal of Medicinal Chemistrypmid:4032428	moderate	consumed	6 sections
—	Searched ClinicalTrials.gov for "PRO-LAD lysergamide" — no resultsabsence		no results	—
—	Searched ClinicalTrials.gov for "PRO-LAD lysergamide" — no resultsabsence		no results	—
—	Searched PubMed for "Hoffman Nichols 1985 lysergamide diethylamide psychedelic analog SAR" — no resultsabsence		no results	—

4Docket

one filing per activity — decisions, correspondence, reports

0012026-04-27revisionRevision 1
Initial LLM generation (v5 pipeline, wiki)
psx:substance/pro-lad/version/1
0022026-06-04proposal29 value proposals approved together
one review action inferred from a shared reviewer and instant — the graph records one activity per proposal
29 items in this filing
- dose_tier · light
- dose_tier · common
- dose_tier · strong
- dose_tier · heavy
- timeline · oral · onset
- timeline · oral · come_up
- timeline · oral · peak
- timeline · oral · plateau
- timeline · oral · resolution
- timeline · oral · afterglow
- toxicity
- dependence · full
- withdrawal
- tolerance
- dosage · oral
- duration · oral · onset
- duration · oral · come_up
- duration · oral · peak
- duration · oral · offset
- duration · oral · total
- duration · oral · aftereffects
- contraindication · psychiatric
- contraindication · psychiatric
- contraindication · neurological
- contraindication · other
- contraindication · other
- contraindication · other
- contraindication · pregnancy_breastfeeding
psx:substance/pro-lad/proposal/dose_tier/18a715e5-d115-41d0-89a3-a868bed95555
0032026-06-04publicationPublication — backfill
psx:substance/pro-lad/pub/f1c0e53d-38cb-4bd6-82fc-11f5588a4e05

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
document	content hash	issued	from version	superseded
emergency	c15c760aabf6f0fcf5b6fc6b…	2026-10-19 20:33	Revision 1	current
info_card	dda4886118b42992503b2ee1…	2026-10-19 20:33	Revision 1	current
notice	f069a9dea47b308467344618…	2026-10-19 20:33	Revision 1	current
emergency	3f0909c25c714d225b4bb3e3…	2026-09-04 04:31	Revision 1	superseded2026-10-19
info_card	9ba6b221d406659576a250c6…	2026-09-04 04:31	Revision 1	superseded2026-10-19
notice	64878b43a1d2932a5305f55b…	2026-09-04 04:31	Revision 1	superseded2026-10-19

PRO-LAD

6Node page

derived from · upstream

feeds · downstream

1Provenance card

2Build

generation run 2026-04-26

research→

draft→

audit→

verify→

simplify→

publish

Selection

Verification

The model's own caveats

Reproduce

generation run 2026-04-27

research→

draft→

audit→

verify→

simplify→

publish

Selection

Verification

The model's own caveats

Reproduce

3Sources

4Docket

5Issued documents

research

draft

audit

verify

simplify

research

draft

audit

verify

simplify